{"schema_version":"secwatch.filing_event.v1","accession":"0001600620-25-000047","form_type":"8-K","ticker":"AUPH","cik":"0001600620","company_name":"Aurinia Pharmaceuticals Inc.","filed_at":"2025-05-12T23:59:59+00:00","discovered_at":"2026-05-14T18:02:48.963169+00:00","generated_at":"2026-05-21T23:40:39.869046+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aurinia Q1 revenue $62.5M (+24% YoY); net income $23.3M vs loss of $10.7M; LUPKYNIS sales up 25%","bullets":["Total revenue $62.5M, up 24% YoY; net product sales of LUPKYNIS were $60.0M (+25% YoY).","Net income $23.3M vs net loss $(10.7)M in Q1 2024; cash flow from operations $1.3M ($12.4M ex-restructuring).","Cash and investments $312.9M; repurchased 5.8M shares for $47.4M in Q1.","Full-year 2025 revenue guidance reaffirmed: $250-$260M; net product sales guidance $240-$250M.","Initial Phase 1 results for dual BAFF/APRIL inhibitor AUR200 expected later this quarter."],"urls":{"canonical":"https://secwatch.observer/filing/0001600620-25-000047","json":"https://secwatch.observer/filing/0001600620-25-000047.json","markdown":"https://secwatch.observer/filing/0001600620-25-000047.md","text":"https://secwatch.observer/filing/0001600620-25-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000047/0001600620-25-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1600620/000160062025000047/auph-20250512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-21T23:40:39.869046+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}